SynthesisInflammatory bowel diseases2026
Prevalence of disability in inflammatory bowel disease: a systematic review and meta-analysis.
Synthesis in Inflammatory bowel diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Progressive Myopenia and Functional Decline in the Winnie Mouse Model of Chronic Colitis.Muscles (Basel, Switzerland) · 2026Article
- The chain mediating roles of stigma and health-promoting lifestyle in the relationship between disability index and posttraumatic growth among patients with inflammatory bowel disease.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsDisability is a multidimensional concept that includes physical, psychological, and social limitations affecting individuals with inflammatory bowel disease (IBD). Disability is shaped by cultural and health care factors that vary across countries and therefore disability prevalence and characteristics may differ globally. We conducted a systematic review with meta-analysis to assess the pooled prevalence of moderate-to-severe disability and investigate how IBD type, disease activity, geographic location, and questionnaire used influenced prevalence.
methodsWe searched MEDLINE, Embase, and Embase Classic (from database inception to March 1, 2025) for cross-sectional, cohort, registry-based, and case-control studies reporting the prevalence of moderate-to-severe disability based on the IBD Disk or IBD-Disability Index in adults with confirmed IBD.
resultsIn total, 17 articles fulfilled the eligibility criteria, including 7897 patients in 17 countries. The pooled prevalence of moderate-to-severe disability in patients with IBD was 29.6% (95% CI, 22.6%-37.1%) and was higher in patients with active IBD (56.9%; 95% CI, 20.3%-89.9%) compared with those with inactive disease (27.0%, 95% CI, 3.3%-62.0%). Based on 3 studies, disease activity increased the odds of moderate-to-severe disability more than 3-fold (odds ratio [OR], 3.13, 95% CI, 1.74-5.64). Stratified by IBD type, moderate-to-severe disability was higher in patients with Crohn disease (36.9%; 95% CI, 25.7%-48.9%) than in ulcerative colitis (30.8%; 95% CI, 19.6%-43.2%), with OR 1.26 (95% CI, 1.06-1.51).
conclusionsThis systematic review is the first, to our knowledge, to show that moderate-to-severe disability affects nearly one-third of patients with IBD, with higher rates in Crohn disease and active disease. Importantly, disability persists in a substantial proportion of patients even during remission, supporting the need for systematic assessment across clinical settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.